When does the Benlysta (belimumab) patent run out?
Publicly available information in the provided sources does not include Benlysta’s patent expiry date(s), so I can’t state when the “Benlysta patent” runs out without additional jurisdiction-specific details (for example, the specific country/territory and which patent numbers or exclusivities you mean).
Does the answer differ by country?
Yes. Drug “patent run out” typically varies by country because patent filings, term calculations (including adjustments), and regulatory exclusivities differ across jurisdictions. To give an accurate date, you’d need to specify which market matters (U.S., EU, UK, Canada, etc.).
Are there multiple dates (patents vs exclusivity)?
Often there are multiple relevant end dates: different patents can expire at different times, and some countries also have regulatory exclusivity periods (separate from patents). Users often ask for the earliest date generics/biosimilars can enter, which may be later than the first patent expiry due to follow-on patents or exclusivity.
What I need from you to pin down the exact date
Tell me:
1) Which country/region you mean (U.S., EU, UK, etc.)
2) Whether you mean the first patent to expire or the earliest date biosimilars could launch
3) If you have them, any patent numbers or product identifiers (helps avoid mixing patents that cover different aspects of belimumab)
With that, I can look up the correct expiry timing for the relevant patents/exclusivity in that jurisdiction.
Sources
No sources were provided with patent-expiry information for Benlysta in this chat.